The recently released top-line results of the SCORE study confirm that treating obesity can significantly reduce the risk of cardiovascular disease. FormHealth CMO Florencia Halperin will dive deeper into how obesity treatment improves cardiometabolic health outcomes during tomorrow's session at The Conference Board NY with Dr. Melani Cheers and Barbara Flitsch. If you're attending the event, don't miss the discussion at 3:10pm. Ready to take a proactive approach to managing employee health while reducing the long-term costs associated with obesity and its related cardiometabolic conditions? Email employers@formhealth.co to learn more.
I am thrilled to head to NYC next week to present at Conference Board's Employee Health Care Conference on "The Heart of Cardiometabolic Care has Always Been Obesity" (Tuesday, April 8th at 3:10PM with my incredible panelists Melani Cheers and Barbara Flitsch). As if on cue to set the stage for our conversation, there is so much new science in the works to support that treating obesity reduces the risk of cardiovascular disease. Top-line results of the SCORE study - Patients with obesity and cardiovascular disease on semaglutide (2.4 mg weekly) had: ✅ Tremendous reductions in myocardial infarction, stroke, hospitalization for heart failure, coronary revascularization ... and ... ✅ 87% reduction in all-cause deaths Look forward to the full published study, but these results look incredible. Treating obesity saves lives!